• Je něco špatně v tomto záznamu ?

Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours

M. Bártů, J. Hojný, N. Hájková, R. Michálková, E. Krkavcová, L. Hadravský, L. Kleissnerová, QH. Bui, I. Stružinská, K. Němejcová, O. Čapoun, M. Šlemendová, P. Dundr

. 2020 ; 10 (1) : 17151. [pub] 20201013

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012037

Grantová podpora
NV17-28404A MZ0 CEP - Centrální evidence projektů

Hepatocyte nuclear factor 1 beta (HNF1B) is a transcription factor which plays a crucial role in nephronogenesis, and its germline mutations have been associated with kidney developmental disorders. However, the effects of HNF1B somatic exonic mutations and its role in the pathogenesis of kidney tumours has not yet been elucidated. Depending on the type of the tumour HNF1B may act as a tumour suppressor or oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using an immunohistochemical approach, and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B in 130 cases of renal tumours (121 renal cell carcinomas, 9 oncocytomas). In the subset of clear cell renal cell carcinoma (ccRCC), decreased HNF1B expression was associated with a higher tumour grade and higher T stage. The mutation analysis revealed no mutations in the analysed samples. Promoter methylation was detected in two ccRCCs and one oncocytoma. The results of our work on a limited sample set suggest that while in papillary renal cell carcinoma HNF1B functions as an oncogene, in ccRCC and chRCC it may act in a tumour suppressive fashion.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012037
003      
CZ-PrNML
005      
20210507104401.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-020-74059-z $2 doi
035    __
$a (PubMed)33051485
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. michaela.bartu@vfn.cz
245    10
$a Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours / $c M. Bártů, J. Hojný, N. Hájková, R. Michálková, E. Krkavcová, L. Hadravský, L. Kleissnerová, QH. Bui, I. Stružinská, K. Němejcová, O. Čapoun, M. Šlemendová, P. Dundr
520    9_
$a Hepatocyte nuclear factor 1 beta (HNF1B) is a transcription factor which plays a crucial role in nephronogenesis, and its germline mutations have been associated with kidney developmental disorders. However, the effects of HNF1B somatic exonic mutations and its role in the pathogenesis of kidney tumours has not yet been elucidated. Depending on the type of the tumour HNF1B may act as a tumour suppressor or oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using an immunohistochemical approach, and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B in 130 cases of renal tumours (121 renal cell carcinomas, 9 oncocytomas). In the subset of clear cell renal cell carcinoma (ccRCC), decreased HNF1B expression was associated with a higher tumour grade and higher T stage. The mutation analysis revealed no mutations in the analysed samples. Promoter methylation was detected in two ccRCCs and one oncocytoma. The results of our work on a limited sample set suggest that while in papillary renal cell carcinoma HNF1B functions as an oncogene, in ccRCC and chRCC it may act in a tumour suppressive fashion.
650    _2
$a karcinom z renálních buněk $x genetika $x patologie $7 D002292
650    _2
$a mutační analýza DNA $x metody $7 D004252
650    _2
$a epigeneze genetická $x genetika $7 D044127
650    _2
$a epigenomika $x metody $7 D057890
650    _2
$a zárodečné mutace $x genetika $7 D018095
650    _2
$a hepatocytární jaderný faktor 1-beta $x genetika $7 D051539
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x patologie $7 D007668
650    _2
$a nádory ledvin $x genetika $x patologie $7 D007680
650    _2
$a promotorové oblasti (genetika) $x genetika $7 D011401
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Hájková, Nikola $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Michálková, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Krkavcová, Eva $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Hadravský, Ladislav $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Kleissnerová, Lenka $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Bui, Quang Hiep $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Čapoun, Otakar $u Department of Urology, General University Hospital in Prague, 12808, Prague, Czech Republic
700    1_
$a Šlemendová, Monika $u Department of Urology, General University Hospital in Prague, 12808, Prague, Czech Republic
700    1_
$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 17151
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33051485 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507104359 $b ABA008
999    __
$a ok $b bmc $g 1650422 $s 1132416
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 17151 $e 20201013 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a NV17-28404A $p MZ0
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...